ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Esketamine

Also written as “Esketamine 84 mg”, “Esketamine 56 mg” and “AM-101”.

Its studies are mostly in Depressive Disorder, Treatment-Resistant · Depressive Disorder, Major · Tinnitus · Depression · Substance-Related Disorders, led by 3 companies.

Drug pageEsketamine: every studyAll 243 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 21, 202045 company-led studies, 2 open or runningNext primary completion: Dec 27, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson412 open or runningphase 4since Oct 21, 2020Jul 11, 2012Dec 27, 2028phase 3 · NCT07716098
Celon Pharmaits history only30 open or runningphase 2since May 21, 2019Jan 8, 2018none ahead
Chengdu Brilliant Pharmaceuticalits history only10 open or runningphase 3since Sep 21, 2023Sep 21, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 27 studies since Jul 11, 2012.

  1. Mar 27, 2017Phase 3 study in Depressive Disorder, MajorNCT03097133 · 230 enrolled · United States, Argentina, Austria and more
  2. Jun 12, 2017Phase 2 study in Depressive Disorder, MajorNCT03185819 · 147 enrolled · United States, Belgium, Brazil and more
  3. Sep 27, 2017Phase 1 study in HealthyNCT03298906 · 16 enrolled · Belgium
  4. Feb 9, 2018Phase 3 study in Depressive Disorder, Treatment-ResistantNCT03434041 · 252 enrolled · United States, China
  5. Feb 12, 2019Phase 3 study in Depressive Disorder, Treatment-ResistantNCT03852160
  6. Feb 21, 2020Phase 1 study in HealthyNCT04282746 · 17 enrolled · Belgium
  7. Apr 6, 2020Phase 3 study in Depressive Disorder, MajorNCT04338321 · 676 enrolled · Argentina, Austria, Belgium and more
  8. Jul 15, 2020Phase 3 study in DepressionNCT04476446 · 41 enrolled · Mexico
  9. Oct 21, 2020Phase 4 study in Depressive Disorder, Treatment-ResistantNCT04599855 · 477 enrolled · United States
  10. Apr 1, 2021Phase 4 study in Depressive Disorder, MajorNCT04829318 · 183 enrolled · Argentina, Belgium, Bulgaria and more
  11. Feb 25, 2022Phase 1 study in DepressionNCT05268497 · United States
  12. Jun 27, 2025Phase 4 study in Depressive Disorder, Treatment-ResistantNCT07053345 · 47 enrolled · South Korea
  13. Nov 11, 2025Phase 3 study in Depressive Disorder, MajorNCT07227454 · 258 planned · United States, Brazil, Hungary and more
  14. Jul 15, 2026Phase 3 study in Depressive Disorder, Treatment-ResistantNCT07716098 · 348 planned · United States, China, Japan and more

Ahead

  1. Dec 27, 2028Primary completion: phase 3 study in Depressive Disorder, Treatment-ResistantNCT07716098
  2. Apr 9, 2031Primary completion: phase 3 study in Depressive Disorder, MajorNCT07227454

TargetBeta

“Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule

Other programs on the same 7 targets

ProgramCompanyFurthest phaseStudies
MemantineruleAbbViephase 429

Studies

All 41 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07716098Depressive Disorder, Treatment-Resistant · United States, China, Japan and more3RecruitingDec 27, 2028348
NCT07227454Depressive Disorder, Major · United States, Brazil, Hungary and more3RecruitingApr 9, 2031258
NCT07053345Depressive Disorder, Treatment-Resistant · South Korea4CompletedJul 13, 202647
NCT05268497Depression · United States1WithdrawnJun 7, 20230
NCT04829318Depressive Disorder, Major · Argentina, Belgium, Bulgaria and more4CompletedJul 22, 2024183
NCT04599855Depressive Disorder, Treatment-Resistant · United States4CompletedJan 31, 2024477
NCT04476446Depression · Mexico3CompletedJun 16, 202341
NCT04338321Depressive Disorder, Major · Argentina, Austria, Belgium and more3CompletedJan 20, 2022676
NCT04282746Healthy · Belgium1CompletedAug 11, 202017
NCT03852160Depressive Disorder, Treatment-Resistant3WithdrawnJul 25, 20210
NCT03434041Depressive Disorder, Treatment-Resistant · United States, China3CompletedApr 13, 2021252
NCT03298906Healthy · Belgium1CompletedNov 27, 201716
NCT03185819Depressive Disorder, Major · United States, Belgium, Brazil and more2CompletedMar 31, 2023147
NCT03097133Depressive Disorder, Major · United States, Argentina, Austria and more3CompletedApr 11, 2019230
NCT03039192Depressive Disorder, Major · United States, Bulgaria, Estonia and more3CompletedDec 18, 2018226
NCT02918318Depression · Japan2CompletedAug 19, 2019202
NCT02919579Depressive Disorder, Major · Netherlands1CompletedJun 29, 201827
NCT02857777Healthy · United States1CompletedJan 27, 201737
NCT02846519Healthy · United States1CompletedMay 28, 201666
NCT02782104Depressive Disorder, Treatment-Resistant · United States, Argentina, Australia and more3CompletedDec 30, 20221,148
NCT02737605Healthy · Germany1CompletedFeb 23, 201762
NCT02682225Substance-Related Disorders · United States1CompletedJan 9, 201755
NCT02674295Healthy · United States1CompletedAug 20168
NCT02611505Hepatic Impairment · United States1CompletedFeb 27, 201724
NCT02606084Renal Insufficiency · United States1CompletedFeb 2, 201832
NCT02497287Depressive Disorder, Treatment-Resistant · United States, Argentina, Australia and more3CompletedOct 28, 2017802
NCT02493868Depressive Disorder, Treatment-Resistant · United States, Belgium, Brazil and more3CompletedFeb 15, 2018719
NCT02422186Depressive Disorder, Treatment-Resistant · United States, Belgium, Brazil and more3CompletedAug 10, 2017139
NCT02418585Depressive Disorder, Treatment-Resistant · United States, Czechia, Germany and more3CompletedJun 1, 2017236
NCT02417064Depressive Disorder, Treatment-Resistant · United States, Belgium, Brazil and more3CompletedFeb 20, 2018346
NCT02345148Healthy · Belgium1CompletedJan 201516
NCT02343289Healthy · Belgium1CompletedApr 201518
NCT02228239Healthy · Netherlands1CompletedDec 201426
NCT02133001Depressive Disorder, Major · United States2CompletedFeb 1, 201668
NCT02129088Healthy · Belgium1CompletedMay 201434
NCT02094378Healthy · Netherlands1CompletedAug 201424
NCT02060929Healthy · Belgium1CompletedJan 201414
NCT01998958Depressive Disorder, Treatment-Resistant · United States, Belgium, Japan2CompletedJul 21, 2015108
NCT01980303Healthy Volunteers · United States1CompletedJan 201429
NCT01780259Healthy · Belgium1CompletedMay 201358
NCT01640080Depressive Disorder, Major · Belgium, Germany, Poland2CompletedJun 3, 201330

How it is read

Names in the registry

  • “Esketamine”, 30 entries
  • “Esketamine 84 mg”, 8 entries
  • “Esketamine 56 mg”, 7 entries
  • “AM-101”, 5 entries
  • “Esketamine 28 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.